See the DrugPatentWatch profile for Austedo
What did Austedo (deutetrabenazine) trials show for tardive dyskinesia?
Austedo’s clinical development included randomized, placebo-controlled studies in people with tardive dyskinesia. Trial results showed that deutetrabenazine reduced abnormal, involuntary movements compared with placebo, with improvements measured using standard movement rating scales used in the tardive dyskinesia clinical setting.
What did Austedo trials show for chorea associated with Huntington’s disease?
In clinical trials for Huntington’s disease–associated chorea, deutetrabenazine reduced chorea severity versus placebo using validated clinical measures. Patients receiving deutetrabenazine showed improvement from baseline relative to the placebo group over the study period.
How consistent were results across studies?
Across Austedo’s randomized controlled programs, the general pattern was the same: deutetrabenazine improved symptom severity compared with placebo in the studied indications. The magnitude of benefit varied by study and dose, but the direction of effect favored deutetrabenazine.
What endpoints were used in the Austedo studies?
The key outcomes in Austedo trials were standardized clinical rating scales for each condition. For tardive dyskinesia, trials used movement-related scales commonly used to quantify dyskinetic symptoms. For Huntington’s disease chorea, trials used chorea severity instruments commonly used in clinical studies for that condition.
What side effects came up in Austedo trials?
Common adverse reactions reported in Austedo’s clinical experience include somnolence/sleepiness, fatigue, diarrhea, and dry mouth, with safety monitoring focused on tolerability and neurologic/psychiatric effects typical of this drug class.
Are there newer trials or expanded evidence beyond the original programs?
Austedo has additional post-approval studies and ongoing evaluation in broader patient populations, but the core efficacy evidence comes from the randomized controlled trials that established benefit in tardive dyskinesia and Huntington’s disease–associated chorea.
Sources
No source links were provided with the question, and I don’t have the specific Austedo trial/result documents you want summarized. If you share which Austedo indication (tardive dyskinesia vs Huntington’s chorea) and any trial identifiers (e.g., NCT numbers) or an excerpt you want interpreted, I can extract and summarize the exact reported results.